JPRN-jRCTs031210097Completed未知
A randomized, controlled trial of rifampicin for non-demented elderly with Alzheimer's disease neuropathology
Iwata Atsushi0 sites15 target enrollmentStarted: May 18, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 15
Study Overview
Brief Summary
The effects of treatment with rifampicin were studied in elderly patients with Alzheimer's disease pathology without dementia in twelve weeks.In the placebo group, there was no trend toward a decrease in CSF NfL, while in the control group, there was a trend toward a decrease, although it not statistical significant.ABeta oligomer and tau oligomer in the CSF also showed an increasing trend in the placebo group, while there was a decreasing trend in the control group, although it not statistical significant.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 65age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •1) Written informed consent to the participation in this research has been provided
- •2) Men and women aged 65 or over at the time of obtaining informed consent
- •3) Person who has been determined to have the pathology of Alzheimer's disease based on amyloid Beta 42/40 and the concentration of p-tau181 in the
- •cerebrospinal fluid
Exclusion Criteria
- •1) Person who has been judged to have dementia by CogState
- •2) Person who has been diagnosed with dementia in the last 5 years
- •3) Person with liver dysfunction with more than 3 times the upper limit of the normal range of ALT or AST
- •4) Person with renal dysfunction with less than 50 ml / min of eGFR
- •5) Person with a history of hypersensitivity to Rifampicin
- •6) Person who has taken Rifampicin within the last 4 weeks
- •7) Person whose inclusion in the research is deemed inappropriate by the principal investigator or sub-investigator
Investigators
Similar Trials
Completed
Phase 1
Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission TomographyAlzheimer DiseaseNCT06022068Karolinska Institutet14
Active, not recruiting
Phase 2
Rapamycin - Effects on Alzheimer's and Cognitive HealthMild Cognitive ImpairmentAlzheimer DiseaseNCT04629495The University of Texas Health Science Center at San Antonio40
Completed
Phase 2
Trial of Rifaximin in Probable Alzheimer's DiseaseAlzheimer's DiseaseNCT03856359Duke University10
Terminated
Phase 3
Study of Rifampicin in Multiple System AtrophyMultiple System AtrophyNCT01287221Phillip Low100
Completed
Phase 3
Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal FluidAlzheimer's DiseaseNCT00439166Hamilton Health Sciences Corporation100